[{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ NorthStar Heathcare","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ NorthStar Heathcare"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Radiolabelled MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ NorthStar","highestDevelopmentStatusID":"1","companyTruncated":"Monopar Therapeutics \/ NorthStar"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Aragen Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Monopar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Monopar Therapeutics"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"mucobuccal tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Monopar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"MNPR-202","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Monopar","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Monopar"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Mucobuccal Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Mucobuccal Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MNPR-202","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Cancer Science Institute of Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MNPR-202","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Cancer Science Institute of Singapore","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Cancer Science Institute of Singapore"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clonidine","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Cancer Science Institute of Singapore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Cancer Science Institute of Singapore","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Cancer Science Institute of Singapore"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"North Star Processing, LLC.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ North Star Processing, LLC","highestDevelopmentStatusID":"5","companyTruncated":"Monopar Therapeutics \/ North Star Processing, LLC"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"MNPR-101","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Lu","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw"}]
Find Clinical Drug Pipeline Developments & Deals by Monopar Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
